Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas

Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriam...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurochirurgica 1990-01, Vol.104 (1-2), p.13-16
Main Authors: von Holst, H, Knochenhauer, E, Blomgren, H, Collins, V P, Ehn, L, Lindquist, M, Norén, G, Peterson, C
Format: Article
Language:English
Subjects:
Adult
Aged
Biological Transport
Brain - metabolism
Brain Neoplasms - metabolism
Brain Neoplasms - surgery
Cell Division - drug effects
Cell Line
Doxorubicin - administration & dosage
Doxorubicin - metabolism
Doxorubicin - pharmacology
Female
Glioma - metabolism
Glioma - surgery
Humans
Injections, Intravenous
Male
Middle Aged
Tumor Cells, Cultured - cytology
Tumor Cells, Cultured - drug effects
Tumor Cells, Cultured - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0.9 and 4.6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient. In an in vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue.
ISSN:0001-6268
0942-0940
DOI:10.1007/BF01842886